,Chapter 1, The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
1. A woman diagnosed with obsessive–
$@1 $@1 $@1 $@1
compulsive disorder has been prescribed oral paroxetine hydrochloride. W
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
hat is the expected effect for this prescription?
$@1 $@1 $@1 $@1 $@1 $@1 $@1
A. Curative effect on symptoms $@1 $@1 $@1
B. Systemic effect on symptoms $@1 $@1 $@1
C. Local effect on symptoms $@1 $@1 $@1
D. Parenteral effect on symptoms $@1 $@1 $@1
ANS: B $ @ 1
Rationale: Drugs that produce systemic effects are taken into the body, circulated
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
through the bloodstream to their sites of action in various body tissues, and ev
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
entually eliminated from the body. Curative agents are given to cure a disease p
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
rocess. In this case, paroxetine hydrochloride will control the symptoms but not c
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ure the disorder. Drugs with local effects, such as sunscreen and local anesthetics
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
, act mainly at the site of application. Paroxetine hydrochloride is not administer
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ed parenterally. Parenteral agents are administered subcutaneously, intramuscularly,
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@
1or intravenously.
$@1
PTS: 1 REF: p. 3, Introduction OBJ: 1 $@1 $@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Understand
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
2. A client has been prescribed an antibiotic. This medication is a naturally occurring
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
substance that has been cheG
mRicA
alDlyEm
SoBdOifOieSd.TW
$@1 haOt Mi s another name for this
.C$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
type of medication?
$@1 $@1
A. Synthetic drug $@1
B. Semisynthetic drug $@1
C. Biotechnology drug $@1
D. Prototype drug $@1
ANS: B $ @ 1
Rationale: Semisynthetic drugs (e.g., many antibiotics) are naturally occurring subs
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
tances that have been chemically modified. Synthetic drugs are more standardized i
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
n their chemical characteristics, more consistent in their effects, and less likely t
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
o produce allergic reactions. Biotechnology drugs involve manipulating DNA and
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@
1RNA and recombining genes into hybrid molecules that can be inserted into livi
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ng organisms. Prototype drugs are the first drug of a particular group to be dev
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
eloped.
PTS: 1 REF: p. 3, Drug Sources OBJ: 1 $@1 $@1 $@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Understand
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
3. Which classification applies to morphine?
$@1 $@1 $@1 $@1
A. Central nervous system depressant $@1 $@1 $@1
B. Central nervous system stimulant $@1 $@1 $@1
, C. Anti-inflammatory
D. Antihypertensive
ANS: A $ @ 1
Rationale: Drugs are classified according to their effects on particular body syste
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ms, their therapeutic uses, and their chemical characteristics. Morphine is classifie
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
d as a central nervous system depressant and will produce this effect in the cli
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ent. A central nervous system stimulant increases attention and raises mood. An a
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
nti-
inflammatory agent decreases inflammation at the site of tissue or joint inflammat
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ion. An antihypertensive agent reduces blood pressure.
$@1 $@1 $@1 $@1 $@1 $@1
PTS: 1 REF:
p. 3, Drug Classifications and Prototypes OBJ: 1
$@1 $@1 $@1 $@1 $@1 $@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Remember
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
G R A D E S B O O S T . C O M
4. A client is administered amoxicillin. The generic name of this medication belongs
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
to which drug group?
$@1 $@1 $@1 $@1
$@1
A. Selective serotonin reuptake inhibitors $@1 $@1 $@1
$@1
B. Diuretics
$@1
C. Penicillins
D. ACE inhibitors
$@1
$@1
$@1
ANS: C $ @ 1
$@1
Rationale: The generic name often indicates the drug group (e.g., drugs with gen
GRADESBOOST.COM
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
eric names ending in ―cillin‖ are penicillins). Selective serotonin reuptake inhibito
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
rs are medications that have antidepressant effects; SSRI is a broad classification,
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
not a generic name. Diuretics are medications that increase urine output; diuretic
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
is a broad classification, not a generic name. ACE inhibitor is the broad classific
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ation for the angiotensin receptor blockers, not the generic name.
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
PTS: 1 REF: p. 3, Drug Names OBJ: 2 $@1 $@1 $@1
$@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Understand
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
5. The administration of diphenhydramine is regulated by which U.S. government agency?
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
A. Public Health Service $@1 $@1
B. Federal Trade Commission $@1 $@1
C. Occupational Safety and Health Administration $@1 $@1 $@1 $@1
D. Food and Drug Administrati $@1 $@1 $@1
on ANS:$@1 $ @ 1 D
, Rationale: The Food and Drug Administration approves drugs for over-the-
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
counter availability, including the transfer of drugs from prescription to OTC sta
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
tus, and may require clinical trials to determine the safety and effectiveness of
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
OTC use. The Public Health Service is regulated by the state to maintain the
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
health of individual citizens of the state. The Federal Trade Commission regulate
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
s imports and exports throughout the nation. The Occupational Safety and Health
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@
1Administration regulates safety within the workplace.
$@1 $@1 $@1 $@1 $@1
PTS: 1 REF:
p. 4, Prescription and Nonprescription Drugs OBJ:
$@1 $@1 4 $@1 $@1 $@1 $@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Understand
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
6. In $@1 the U.S., the administration of anabolic steroids is regulated by which law?
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
A. The Food, Drug, and Cosmetic Act of 1938
$@1 $@1 $@1 $@1 $@1 $@1 $@1
B. The Comprehensive Drug Abuse Prevention and Control Act
$@1 $@1 $@1 $@1 $@1 $@1 $@1
C. The Harrison Narcotic Act
$@1 $@1 $@1
G R A D E S B O O S T . C O M
D. The Sherley Amendment
$@1
$@1 $@1
$@1
ANS: B $ @ 1
$@1
Rationale: The Comprehensive Drug Abuse Prevention and Control Act regulates
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
the manufacture and distribution of narcotics, stimulants, depressants, hallucinogens
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
, and anabolic steroids. The Food, Drug, and Cosmetic Act of 1938 revised and
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $
broadened FDA powers and responsibilities, giving the FDA control over drug sa
$@1
@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
fety. The Harrison Narcotic Act restricted the importation, manufacture, sale, and
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
use of opium, cocaine, marijuana, and other drugs that the act d e f i Gn eRd Aa Ds E
naSrcB
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
oO
tiO
csS Th.eCSOhM
. T erley Amendment of 1912 prohibited fraudulent claims of drug effectiv
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
eness.
$@1
$@1
PTS: 1 REF:
$@1
p. 4, Prescription and Nonprescription Drugs OBJ:
$@1 $@1 3 $@1 $@1 $@1 $@1
$@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Remember
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
7. A nurse is responsible for maintaining an accurate count and record of the c
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ontrolled substances on the nursing division. This nursing action is regulated b
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
y which U.S. law or agency?
$@1 $@1 $@1 $@1 $@1
A. The Food, Drug, and Cosmetic Act of 1938
$@1 $@1 $@1 $@1 $@1 $@1 $@1
B. The Public Health Service
$@1 $@1 $@1
C. The Drug Enforcement Administration
$@1 $@1 $@1
D. The Sherley Amendme $@1 $@1
nt ANS:
$@1 $ @ 1 C
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
1. A woman diagnosed with obsessive–
$@1 $@1 $@1 $@1
compulsive disorder has been prescribed oral paroxetine hydrochloride. W
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
hat is the expected effect for this prescription?
$@1 $@1 $@1 $@1 $@1 $@1 $@1
A. Curative effect on symptoms $@1 $@1 $@1
B. Systemic effect on symptoms $@1 $@1 $@1
C. Local effect on symptoms $@1 $@1 $@1
D. Parenteral effect on symptoms $@1 $@1 $@1
ANS: B $ @ 1
Rationale: Drugs that produce systemic effects are taken into the body, circulated
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
through the bloodstream to their sites of action in various body tissues, and ev
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
entually eliminated from the body. Curative agents are given to cure a disease p
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
rocess. In this case, paroxetine hydrochloride will control the symptoms but not c
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ure the disorder. Drugs with local effects, such as sunscreen and local anesthetics
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
, act mainly at the site of application. Paroxetine hydrochloride is not administer
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ed parenterally. Parenteral agents are administered subcutaneously, intramuscularly,
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@
1or intravenously.
$@1
PTS: 1 REF: p. 3, Introduction OBJ: 1 $@1 $@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Understand
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
2. A client has been prescribed an antibiotic. This medication is a naturally occurring
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
substance that has been cheG
mRicA
alDlyEm
SoBdOifOieSd.TW
$@1 haOt Mi s another name for this
.C$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
type of medication?
$@1 $@1
A. Synthetic drug $@1
B. Semisynthetic drug $@1
C. Biotechnology drug $@1
D. Prototype drug $@1
ANS: B $ @ 1
Rationale: Semisynthetic drugs (e.g., many antibiotics) are naturally occurring subs
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
tances that have been chemically modified. Synthetic drugs are more standardized i
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
n their chemical characteristics, more consistent in their effects, and less likely t
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
o produce allergic reactions. Biotechnology drugs involve manipulating DNA and
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@
1RNA and recombining genes into hybrid molecules that can be inserted into livi
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ng organisms. Prototype drugs are the first drug of a particular group to be dev
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
eloped.
PTS: 1 REF: p. 3, Drug Sources OBJ: 1 $@1 $@1 $@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Understand
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
3. Which classification applies to morphine?
$@1 $@1 $@1 $@1
A. Central nervous system depressant $@1 $@1 $@1
B. Central nervous system stimulant $@1 $@1 $@1
, C. Anti-inflammatory
D. Antihypertensive
ANS: A $ @ 1
Rationale: Drugs are classified according to their effects on particular body syste
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ms, their therapeutic uses, and their chemical characteristics. Morphine is classifie
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
d as a central nervous system depressant and will produce this effect in the cli
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ent. A central nervous system stimulant increases attention and raises mood. An a
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
nti-
inflammatory agent decreases inflammation at the site of tissue or joint inflammat
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ion. An antihypertensive agent reduces blood pressure.
$@1 $@1 $@1 $@1 $@1 $@1
PTS: 1 REF:
p. 3, Drug Classifications and Prototypes OBJ: 1
$@1 $@1 $@1 $@1 $@1 $@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Remember
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
G R A D E S B O O S T . C O M
4. A client is administered amoxicillin. The generic name of this medication belongs
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
to which drug group?
$@1 $@1 $@1 $@1
$@1
A. Selective serotonin reuptake inhibitors $@1 $@1 $@1
$@1
B. Diuretics
$@1
C. Penicillins
D. ACE inhibitors
$@1
$@1
$@1
ANS: C $ @ 1
$@1
Rationale: The generic name often indicates the drug group (e.g., drugs with gen
GRADESBOOST.COM
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
eric names ending in ―cillin‖ are penicillins). Selective serotonin reuptake inhibito
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
rs are medications that have antidepressant effects; SSRI is a broad classification,
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
not a generic name. Diuretics are medications that increase urine output; diuretic
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
is a broad classification, not a generic name. ACE inhibitor is the broad classific
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ation for the angiotensin receptor blockers, not the generic name.
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
PTS: 1 REF: p. 3, Drug Names OBJ: 2 $@1 $@1 $@1
$@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Understand
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
5. The administration of diphenhydramine is regulated by which U.S. government agency?
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
A. Public Health Service $@1 $@1
B. Federal Trade Commission $@1 $@1
C. Occupational Safety and Health Administration $@1 $@1 $@1 $@1
D. Food and Drug Administrati $@1 $@1 $@1
on ANS:$@1 $ @ 1 D
, Rationale: The Food and Drug Administration approves drugs for over-the-
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
counter availability, including the transfer of drugs from prescription to OTC sta
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
tus, and may require clinical trials to determine the safety and effectiveness of
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
OTC use. The Public Health Service is regulated by the state to maintain the
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
health of individual citizens of the state. The Federal Trade Commission regulate
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
s imports and exports throughout the nation. The Occupational Safety and Health
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@
1Administration regulates safety within the workplace.
$@1 $@1 $@1 $@1 $@1
PTS: 1 REF:
p. 4, Prescription and Nonprescription Drugs OBJ:
$@1 $@1 4 $@1 $@1 $@1 $@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Understand
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
6. In $@1 the U.S., the administration of anabolic steroids is regulated by which law?
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
A. The Food, Drug, and Cosmetic Act of 1938
$@1 $@1 $@1 $@1 $@1 $@1 $@1
B. The Comprehensive Drug Abuse Prevention and Control Act
$@1 $@1 $@1 $@1 $@1 $@1 $@1
C. The Harrison Narcotic Act
$@1 $@1 $@1
G R A D E S B O O S T . C O M
D. The Sherley Amendment
$@1
$@1 $@1
$@1
ANS: B $ @ 1
$@1
Rationale: The Comprehensive Drug Abuse Prevention and Control Act regulates
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
the manufacture and distribution of narcotics, stimulants, depressants, hallucinogens
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
, and anabolic steroids. The Food, Drug, and Cosmetic Act of 1938 revised and
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $
broadened FDA powers and responsibilities, giving the FDA control over drug sa
$@1
@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
fety. The Harrison Narcotic Act restricted the importation, manufacture, sale, and
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
use of opium, cocaine, marijuana, and other drugs that the act d e f i Gn eRd Aa Ds E
naSrcB
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
oO
tiO
csS Th.eCSOhM
. T erley Amendment of 1912 prohibited fraudulent claims of drug effectiv
$@1
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
eness.
$@1
$@1
PTS: 1 REF:
$@1
p. 4, Prescription and Nonprescription Drugs OBJ:
$@1 $@1 3 $@1 $@1 $@1 $@1
$@1
NAT: Client Needs: Physiological Integrity: Pharmacological and Parenteral Th
$ @ 1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
$@1
erapies TOP: Chapter: 1: The Foundation of Pharmacology: Quality and Safety
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
KEY: Integrated Process: Nursing Process
$ @ 1 $@1 $@1 $@1
BLM: Cognitive Level: Remember
$ @ 1 NOT: Multiple Choice $@1 $@1 $ @ 1 $@1
7. A nurse is responsible for maintaining an accurate count and record of the c
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
ontrolled substances on the nursing division. This nursing action is regulated b
$@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1 $@1
y which U.S. law or agency?
$@1 $@1 $@1 $@1 $@1
A. The Food, Drug, and Cosmetic Act of 1938
$@1 $@1 $@1 $@1 $@1 $@1 $@1
B. The Public Health Service
$@1 $@1 $@1
C. The Drug Enforcement Administration
$@1 $@1 $@1
D. The Sherley Amendme $@1 $@1
nt ANS:
$@1 $ @ 1 C
